Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 40Terminated 19Recruiting 11Active not recruiting 9Withdrawn 7Unknown 4Not yet recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Liver Neoplasms 1Fibrolamellar hepatocellular carcinoma 1Carcinoma 1

Interventions

Cisplatin 122Carboplatin 121Drug Therapy 118Bevacizumab 105Capecitabine 99Oxaliplatin 97Radiotherapy 95Paclitaxel 88Gemcitabine 88tislelizumab 87Cyclophosphamide 86Specimen Handling 80pembrolizumab 76toripalimab 67Magnetic Resonance Spectroscopy 65Fluorouracil 62sintilimab 59Injections 57Surgical Procedures, Operative 56Docetaxel 54anlotinib 51130-nm albumin-bound paclitaxel 48Immune Checkpoint Inhibitors 47fludarabine 46Standard of Care 45Pemetrexed 43Blood Specimen Collection 43Biopsy 43venetoclax 41lenvatinib 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × poly ICLC × Clear all
NCT07300475 2026-05-07

Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients

Washington University School of Medicine

Phase 1 Not yet recruiting
30 enrolled
Breast

Triple Negative Breast Neoplasms

NCT07430202 2026-05-06

A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Not yet recruiting
27 enrolled
Gastrointestinal

Fibrolamellar hepatocellular carcinoma, Carcinoma, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡